Servier strengthens its R&D pipeline with Symphogen acquisition

Symphogen becomes the antibody center of excellence within Servier.

According to Servier, the move will strengthen its antibody capabilities, as it is set to gain full ownership of Symphogen’s proprietary pipeline of oncology and immuno-oncology programs and the company's antibody discovery and development platform. The acquisition will also ensure that Symphogen’s antibody discovery and early-development platform is fully utilized.

Once the acquisition is complete, Symphogen will become Servier’s antibody center of excellence for its therapeutic areas; it will also operate as a standalone organization within the Servier Group, maintain its headquarters in Ballerup, Denmark, and continue to rely on its current and experienced employees.

“The acquisition of Symphogen is an important step for Servier to meet its strategic ambitions to become a recognized player in oncology. Antibody-based therapies remain a key therapeutic modality within oncology and immuno-oncology, and with Symphogen’s strong antibody capabilities, this acquisition will boost significantly our R&D in oncology and in our other therapeutic areas," said Olivier Laureau, President of Servier.

Servier and Symphogen have been engaged in a strategic immuno-oncology collaboration for more than 2 years.